Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 72% Improvement Relative Risk MedInCell et al. NCT05305560 SAIVE Ivermectin RCT Prophylaxis Favors ivermectin Favors control
MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population
MedInCell Press Release (Preprint), SAIVE, NCT05305560 (history)
MedInCell, MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a.., Press Release (Preprint), SAIVE, NCT05305560
Jan 2023   Source   PDF  
  All Studies   Meta
PEP RCT 399 patients in Bulgaria showing significantly lower COVID-19 cases with ivermectin prophylaxis. Limited information is currently available.
risk of case, 71.6% lower, RR 0.28, p < 0.001, treatment 30 of 200 (15.0%), control 105 of 199 (52.8%), NNT 2.6.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
MedInCell et al., 5 Jan 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Bulgaria, preprint, 1 author, study period March 2022 - November 2022, dosage 200μg/kg day 1, 7mg days 2-28, trial NCT05305560 (history) (SAIVE).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population Euronext: MEDCL • Montpellier - France • January 5, 2023 – 8:00 pm CET The study conducted in 399 participants met its primary efficacy endpoint with a reduction of 72% of COVID-19 infection in the group treated with daily oral administration of ivermectin compared to the placebo group Ivermectin administered for 28 days demonstrated acceptable safety and tolerability without any unexpected safety signals The SAIVE study was conducted to support mdc-TTG program, whose objective is to provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell’s proprietary technology, BEPO® Note: this publication is not a recommendation to use ivermectin against Covid-19. The SAIVE Trial (NCT 05305560) is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical study, evaluating the safety and efficacy of ivermectin tablets taken orally for 28 days, under the oversight of a U.S. based independent Data Monitoring Committee. The study was conducted in Bulgaria between March and November 2022. All participants were unvaccinated adults and had been exposed to the virus within 5 days of screening after documented close contact with a person who had a PCR-confirmed SARS-CoV-2 infection. Participants randomized to ivermectin group showed a highly statistically significant reduction (72%) of laboratory-confirmed infections between baseline and Day 28 (30/200) versus placebo (105/199), the study's primary endpoint, with p<0,0001. No safety signals related to daily intake of ivermectin, 200 microgram/kg on Day 1 then 100 microgram/kg daily from Day 2 to Day 28 were identified during the study. The company plans to share the final analysis of the study in a peer-reviewed publication at a later date. “The SAIVE study provides encouraging data demonstrating efficacy and safety of ivermectin in prevention of Covid-19 infection in a postexposure situation. It supports the development of a long-acting injectable, said Christophe Douat, CEO of MedinCell. Such a longacting injectable would provide a complementary tool against Covid-19. Several candidate formulations of ivermectin are ready for clinical batch manufacturing to start regulatory preclinical and clinical development. We will be reviewing the strategy for this asset based on this top line result and the upcoming comprehensive analysis of the study.” About MedinCell MedinCell is a pharmaceutical technology company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. U.S. FDA approval for the first product using BEPO® technology for patients with schizophrenia is expected in H1 2023. Two other products are in clinical Phase 3. In addition, several programs should reach the clinic in 2023 and 2024, including two Global Health initiatives in woman health (contraception) and malaria, supported by the Bill & Melinda Gates Foundation and Unitaid respectively. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, and to a reduction in the quantity of medication required. The BEPO ® technology makes it possible..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop